Cited by 404Atrial Fibrillation Management and OutcomesVenous Thromboembolism Diagnosis and ManagementAcute Ischemic Stroke Management

The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.

Management of atrial fibrillation in seven European countries after the publication of the 2010 ESC Guidelines on atrial fibrillation: primary results of the PREvention oF thromboemolic events—European Registry in Atrial Fibrillation (PREFER in AF)

Open access

Kirchhof, Paulus, Ammentorp, Bettina, Darius, Harald, De Caterina, Raffaele, Le Heuzey, Jean-Yves, Schilling, Richard John, Schmitt, Josef, Zamorano, Jose Luis·2014·EP Europace

DOI 10.1093/europace/eut263PMC PMC3864758

Open this paper in CoChat — free account Open PDF

Abstract

AIMS: We sought to describe the management of patients with atrial fibrillation (AF) in Europe after the release of the 2010 AF Guidelines of the European Society of Cardiology. METHODS AND RESULTS: The PREFER in AF registry enrolled consecutive patients with AF from January 2012 to January 2013 in 461 centres in seven European countries. Seven thousand two hundred and forty-three evaluable patients were enrolled, aged 71.5 ± 11 years, 60.1% male, CHA2DS2VASc score 3.4 ± 1.8 (mean ± standard deviation). Thirty per cent patients had paroxysmal, 24.0% had persistent, 7.2% had long-standing persistent, and 38.8% had permanent AF. Oral anticoagulation was used in the majority of patients: 4799 patients (66.3%) received a vitamin K antagonist (VKA) as mono-therapy, 720 patients a combination of VKA and antiplatelet agents (9.9%), 442 patients (6.1%) a new oral anticoagulant drugs (NOAC). Antiplatelet agents alone were given to 808 patients (11.2%), no antithrombotic therapy to 474 patients (6.5%). Of 7034 evaluable patients, 5530 (78.6%) patients were adequately rate controlled (mean heart rate 60-100 bpm). Half of the patients (50.7%) received rhythm control therapy by electrical cardioversion (18.1%), pharmacological cardioversion (19.5%), antiarrhythmic drugs (amiodarone 24.1%, flecainide or propafenone 13.5%, sotalol 5.5%, dronedarone 4.0%), and catheter ablation (5.0%). CONCLUSION: The management of AF patients in 2012 has adapted to recent evidence and guideline recommendations. Oral anticoagulant therapy with VKA (majority) or NOACs is given to over 80% of eligible patients, including those at risk for bleeding. Rate is often adequately controlled, and rhythm control therapy is widely used.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1093/europace/eut263

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Guidelines for the management of atrial fibrillation
Authors/Task Force Members, Camm, A. J., Kirchhof, P. F., Lip, G. Y. H., Schotten, U., Savelieva, I., Ernst, S., Gelder, I. C. V., Al‐Attar, N., Hindricks, G., et al. (2010) · European Heart Journal · doi:10.1093/eurheartj/ehq278 · Cited by 5,924
Lifetime Risk for Development of Atrial Fibrillation: The Framingham Heart Study
Lloyd-Jones, D. M., Wang, T. J., Leip, E. P., Larson, M. G., Levy, D., Vasan, R. S., D’Agostino, R. B., Massaro, J. M., Beiser, A., Wolf, P. A., et al. (2004) · Circulation · doi:10.1161/01.cir.0000140263.20897.42 · Cited by 2,041
Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study
Heeringa, J., van der Kuip, D. A. M., Hofman, A., Kors, J. A., van Herpen, G., Stricker, B. H. C., Stijnen, T., Lip, G. Y. H., & Witteman, J. C. M. (2006) · European Heart Journal · doi:10.1093/eurheartj/ehi825 · Cited by 1,939
Guidelines for the management of atrial fibrillation
Authors/Task Force Members, Camm, A. J., Kirchhof, P. F., Lip, G. Y. H., Schotten, U., Savelieva, I., Ernst, S., Gelder, I. C. V., Al‐Attar, N., Hindricks, G., et al. (2010) · EP Europace · doi:10.1093/europace/euq350 · Cited by 1,764
Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study
Olesen, J. B., Lip, G. Y. H., Hansen, M. L., Hansen, P. R., Tolstrup, J. S., Lindhardsen, J., Selmer, C., Ahlehoff, O., Olsen, A.-M. S., Gislason, G. H., et al. (2011) · BMJ · doi:10.1136/bmj.d124 · Cited by 1,428
Lenient versus strict rate control in patients with atrial fibrillation
Van Gelder, I. C., Groenveld, H. F., Crijns, H. J. G. M., Tuininga, Y. S., Tijssen, J. G. P., Alings, A. M., Hillege, H. L., Bergsma-Kadijk, J. A., Cornel, J. H., Kamp, O., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001337 · Cited by 1,033
Atrial fibrillation management: a prospective survey in ESC Member Countries
Nieuwlaat, R., Capucci, A., Camm, A. J., Olsson, S. B., Andresen, D., Davies, D. W., Cobbe, S. M., BREITHARDT, G. E., Heuzey, J. L., Prins, M. H., et al. (2005) · European Heart Journal · doi:10.1093/eurheartj/ehi505 · Cited by 825
Progression From Paroxysmal to Persistent Atrial Fibrillation
de Vos, C. B., Pisters, R., Nieuwlaat, R., Prins, M. H., Tieleman, R. G., Coelen, R. J. S., Heijkant, A. C. V. D., Allessie, M. A., & Crijns, H. J. G. M. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.11.040 · Cited by 720
Risk Profiles and Antithrombotic Treatment of Patients Newly Diagnosed with Atrial Fibrillation at Risk of Stroke: Perspectives from the International, Observational, Prospective GARFIELD Registry
Kakkar, A. K., Mueller, I., Bassand, J., Fitzmaurice, D. A., Goldhaber, S. Z., Goto, S., Haas, S. K., Hacke, W., Lip, G. Y. H., Mantovani, L. G., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0063479 · Cited by 449
The Registry of the German Competence NETwork on Atrial Fibrillation: Patient characteristics and initial management
Nabauer, M., Gerth, A., Limbourg, T., Schneider, S., Oeff, M., Kirchhof, P., Goette, A., Lewalter, T., Ravens, U., Meinertz, T., et al. (2008) · Europace · doi:10.1093/europace/eun369 · Cited by 427

Flagged first, then by citations

Show all 24 references

Research works printed but not linked: 1

Lip, 2013, EUR Observational research programme: atrial fibrillation general registry pilot phase, Eur H J, 34, 794

Sorted by citations

Items 201–300 of 404

Antithrombotic therapy in atrial fibrillation patients with coronary artery disease: shifting paradigm to a “less is more” concept regimen
Kawakami, S., Yasuda, S., & Ogawa, H. (2020) · Journal of Cardiology · doi:10.1016/j.jjcc.2020.03.001 · Cited by 11
Combination of Atrial Fibrillation and Coronary Heart Disease in Patients in Clinical Practice: Comorbidities, Pharmacotherapy and Outcomes (Data from the REСVASA Registries)
Loukianov, М. М., Martsevich, S. Y., Andreenko, Е. Y., Yakushin, S. S., Vorobyev, A. N., Pereverzeva, K. G., Zagrebelny, A. V., Okshina, Е. Y., Yakusevich, V. V., Yakusevich, V. V., et al. (2021) · Rational Pharmacotherapy in Cardiology · doi:10.20996/1819-6446-2021-10-03 · Cited by 9
Anticoagulation in atrial fibrillation and chronic heart failure
Boos, C. J., & Brown, L. (2015) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000245 · Cited by 9
Antithrombotic strategies for preventing long-term major adverse cardiovascular events in patients with non-valvular atrial fibrillation who undergo percutaneous coronary intervention
Pareek, M., Bhatt, D. L., ten Berg, J. M., Kristensen, S. D., & Grove, E. L. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1329822 · Cited by 10
Management of oral anticoagulation in very old patients with non valvular atrial fibrillation related acute ischemic stroke
Vannucchi, V., Moroni, F., Grifoni, E., Marcucci, R., Landini, G., Prisco, D., & Masotti, L. (2019) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-019-01972-0 · Cited by 9
Changes in anticoagulant prescription in Dutch patients with recent-onset atrial fibrillation: observations from the GARFIELD-AF registry
on behalf of the GARFIELD-AF Investigators, Seelig, J., Verheugt, F. W. A., Hemels, M. E. W., Illingworth, L., Lucassen, A. M. J., Adriaansen, H. J., Bongaerts, M. C. M., Pieterse, M., Herrman, J.-P., et al. (2020) · Thrombosis Journal · doi:10.1186/s12959-020-00218-x · Cited by 9
Quality indicators in the management of atrial fibrillation: the BALKAN-AF survey
Kozieł, M., Mihajlovic, M., Nedeljkovic, M. A., Pavlović, N., Paparisto, V., Musić, L., Trendafilova, E., Dan, A. R., Kušljugić, Z., Dan, G., et al. (2021) · International Journal of Cardiology · doi:10.1016/j.ijcard.2021.02.041 · Cited by 8
Education of healthcare professionals to improve guideline adherence in atrial fibrillation: the STEEER-AF cluster-randomized clinical trial
Kotecha, D., Bunting, K. V., Mehta, S. P., Sommer, P., Sterlinski, M. M., Rajappan, K., Mont, L., Guasch, E., Bovéda, S., Boriani, G., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-03751-2 · Cited by 8
Testing the therapeutic equivalence of novel oral anticoagulants for thromboprophylaxis in orthopedic surgery and for prevention of stroke in atrial fibrillation
Messori, A., Fadda, V., Maratea, D., Trippoli, S., & Marinai, C. (2014) · International Journal of Clinical Pharmacology and Therapeutics · doi:10.5414/cp202183 · Cited by 8
Effectiveness, safety and costs of thromboembolic prevention in patients with non-valvular atrial fibrillation: phase I ESC-FA protocol study and baseline characteristics of a cohort from a primary care electronic database
Giner‐Soriano, M., Urgell, C. V., Roso‐Llorach, A., Morros, R., Capellà, D., Cervelló, X. C., González, I. F., Troncoso‐Mariño, A., Diogène, E., Elorza, J. M., et al. (2016) · BMJ Open · doi:10.1136/bmjopen-2015-010144 · Cited by 8
LAA occluder device for stroke prevention: Data on WATCHMAN and other LAA occluders
Bergmann, M. (2017) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2017.03.006 · Cited by 8
Diagnostics, treatment and secondary prevention of ischemic stroke in the Silesian Province, Poland between 2009 and 2015
Labuz-Roszak, B. M., Starostka-Tatar, A., Lasek‐Bal, A., Gierlotka, M. J., Gąsior, M., & Skrzypek, M. (2017) · Neurologia i Neurochirurgia Polska · doi:10.1016/j.pjnns.2017.11.003 · Cited by 8
The future of anticoagulation management in atrial fibrillation in Europe: An assessment of today's challenges with recommendations for the future
Lichten, C. A., Castle‐Clarke, S., Manville, C. M., Horváth, V., Robin, E., Krapels, J., Parks, S., Sim, M., van Zijverden, O., & Chataway, J. (2015) · Rand health quarterly · doi:10.7249/rhq-05-02-02 · Cited by 8
Heterogeneity of diabetes as a risk factor for major adverse cardiovascular events in anticoagulated patients with atrial fibrillation: an analysis of the ARISTOTLE trial
Caterina, R. D., Patti, G., Westerbergh, J., Horowitz, J. D., Ezekowitz, J. A., Lewis, B. S., Lópes, R. D., McMurray, J. J. V., Atar, D., Bahit, M. C., et al. (2020) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvaa140 · Cited by 8
Barriers to prescribing oral anticoagulants to inpatients aged 80 years and older with nonvalvular atrial fibrillation: a cross-sectional study
Xia, X., Wang, L., Lin, T., Yue, J., Yang, Z., Mi, C., Liao, Z., Chen, Y., Ge, N., & Wu, C. (2022) · BMC Geriatrics · doi:10.1186/s12877-022-02965-0 · Cited by 8
Oral anticoagulant treatment in rheumatoid arthritis patients with atrial fibrillation results of an international audit
Semb, A. G., Rollefstad, S., Sexton, J., Ikdahl, E., Crowson, C. S., van Riel, P. L. C. M., Kitas, G. D., Graham, I. M., Kerola, A. M., Karpouzas, G. A., et al. (2022) · IJC Heart & Vasculature · doi:10.1016/j.ijcha.2022.101117 · Cited by 8
Antithrombotic Therapy in Patients with Atrial Fibrillation and Acute Coronary Syndrome
Bor, W. L., & Gorog, D. A. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9072020 · Cited by 8
The cost of warfarin treatment for stroke prevention in patients with non-valvular atrial fibrillation in Russia from a collective perspective
Brière, J., Bowrin, K., Wood, R. P., Roberts, J. S., & Tatarsky, B. A. (2017) · Journal of Medical Economics · doi:10.1080/13696998.2017.1290641 · Cited by 8
Eurasian clinical guidelines for the diagnosis and treatment of atrial fibrillation in adult patients (2025)
Sp, G., Панченко, Е. П., Mironov, N. Y., Михайловна, Б. М., Gagloeva, D. A., Elfimova, E. M., Станиславовна, К. Е., Laiovich, L. I., Litvin, A. Y., Maykov, E. B., et al. (2025) · Eurasian heart journal · doi:10.38109/2225-1685-2025-3-6-77 · Cited by 8
Apixaban, edoxaban and rivaroxaban but not dabigatran are associated with higher mortality compared to vitamin‐K antagonists: A retrospective German claims data analysis
Engelbertz, C. M., Marschall, U., Feld, J., Makowski, L., Lange, S. A., Freisinger, E., Gerß, J., Breithardt, G., Faldum, A., Reinecke, H., et al. (2024) · Journal of Internal Medicine · doi:10.1111/joim.20006 · Cited by 7
Use of oral anticoagulation therapy in the first 3 months after the diagnosis of atrial fibrillation in Israel: A population‐based study
Kezerle, L., Tsadok, M. A., Senderey, A. B., Hoshen, M., Leventer‐Roberts, M., Reges, O., Leibowitz, M., & Haim, M. (2020) · Journal of Cardiovascular Electrophysiology · doi:10.1111/jce.14452 · Cited by 7
Utilization and long‐term persistence of direct oral anticoagulants among patients with nonvalvular atrial fibrillation and liver disease
Douros, A., Cui, Y. J., Platt, R. W., Filion, K. B., Sebastiani, G., & Renoux, C. (2021) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15046 · Cited by 7
Clinical Performance of Oral Anticoagulants in Elderly with Atrial Fibrillation and Low Body Weight: Insight into Italian Cohort of PREFER-AF and PREFER-AF Prolongation Registries
Russo, V., Attena, E., Baroni, M., Trotta, R., Manu, M. C., Kirchhof, P. F., & Caterina, R. D. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11133751 · Cited by 7
Association of Concomitant Coronary Artery Disease With Cardiovascular Events in Patients With Atrial Fibrillation ― The Fushimi AF Registry ―
Masunaga, N., Ogawa, H., Minami, K., Ishigami, K., Ikeda, S., Doi, K., Hamatani, Y., Yoshizawa, T., Ide, Y., Fujino, A., et al. (2022) · Circulation Journal · doi:10.1253/circj.cj-22-0180 · Cited by 8
Prevalence and Impact of Poorly Controlled Modifiable Risk Factors Among Patients Who Underwent Atrial Fibrillation Ablation
Stout, K. M., Almerstani, M., Adomako, R., Shin, D., Aroudaky, A., Tandon, H. K., Alziadin, N., Schleifer, J. W., Payne, J., Easley, A., et al. (2023) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2023.04.024 · Cited by 8
Persistence with VKA treatment in newly treated atrial fibrillation patients: an analysis based on a large sample of 38,076 German patients
Wilke, T., Groth, A., Fuchs, A., Pfannkuche, M., & Maywald, U. (2017) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-017-2307-2 · Cited by 7
Optimal antithrombotic treatment of patients with atrial fibrillation undergoing percutaneous coronary intervention: triple therapy is too much!
Jacobs, M. S., & Tieleman, R. G. (2018) · Netherlands Heart Journal · doi:10.1007/s12471-018-1120-6 · Cited by 7
Antithrombotic management and outcomes of patients with atrial fibrillation treated with NOACs early at the time of market introduction: Main results from the PREFER in AF Prolongation Registry
Renda, G., Pecen, L., Patti, G., Ricci, F., Kotecha, D., Siller-Matula, J. M., Schnabel, R. B., Wachter, R., Sellal, J., Rohla, M., et al. (2020) · Internal and Emergency Medicine · doi:10.1007/s11739-020-02442-9 · Cited by 7
Oral anticoagulation after catheter ablation of atrial fibrillation: caught in the attribution trap?
Kirchhof, P. F., Purmah, Y., & Verma, A. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu443 · Cited by 7
Diseño y características basales del estudio REGUEIFA (Registro Gallego Intercéntrico de Fibrilación Auricular)
García‐Seara, J., Melchor, L. G., Caamaño, M. V., Windcheid, E. F.-O., Piñeiro‐Portela, M., Babarro, E. G., Cabanas‐Grandío, P., Duran, Ö., Prada‐Delgado, Ó., Teja, J. E., et al. (2020) · REC CardioClinics · doi:10.1016/j.rccl.2020.10.015 · Cited by 6
Effect of Early Direct Current Cardioversion on the Recurrence of Atrial Fibrillation in Patients With Persistent Atrial Fibrillation
Osmanagic, A., Möller, S., Osmanagic, A., Sheta, H. M., Vinther, K. H., & Egstrup, K. (2015) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2015.04.013 · Cited by 6
Comparison of health-related quality of life in patients with atrial fibrillation treated with catheter ablation or antiarrhythmic drug therapy: a systematic review and meta-analysis protocol
Allan, K. S., Henry, S., Aves, T., Banfield, L. E., Victor, J. C., Dorian, P., Healey, J. S., Andrade, J. G., Carroll, S. L., & McGillion, M. H. (2017) · BMJ Open · doi:10.1136/bmjopen-2017-017577 · Cited by 6
Time trends in antithrombotic therapy prescription patterns: Real-world monocentric study in hospitalized patients with atrial fibrillation
Abrignani, M. G., Lombardo, A., Braschi, A., Renda, N., Abrignani, V., & Lombardo, R. M. (2022) · World Journal of Cardiology · doi:10.4330/wjc.v14.i11.576 · Cited by 6
New oral anticoagulants versus Warfarin in patients undergoing cardioversion of atrial fibrillation
Andò, G., & Trio, O. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.09.126 · Cited by 6
Thromboembolic Risk in Nonanticoagulated Patients With Atrial Fibrillation and Valvular Heart Disease
Melgaard, L., Overvad, T. F., Jensen, M., Lip, G. Y. H., Larsen, T. B., & Nielsen, P. B. (2020) · JACC. Clinical electrophysiology · doi:10.1016/j.jacep.2020.07.005 · Cited by 6
Sex and Stroke Risk in Atrial Fibrillation
Schnabel, R. B., & Benjamin, E. J. (2018) · JACC. Clinical electrophysiology · doi:10.1016/j.jacep.2018.03.002 · Cited by 5
Association Between Atrial Fibrillation Symptoms and Clinical Outcomes: A Prospective Multicenter Registry Study
Lee, S. J., Park, J., Park, J., Kang, K., Uhm, J., Choi, E., Kim, J., Kim, J., Lee, Y. S., Park, H. W., et al. (2024) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2024.02.026 · Cited by 5
New oral anticoagulants versus vitamin K antagonists before cardioversion of atrial fibrillation: a meta-analysis of data from 4 randomized trials
Andò, G., Trio, O., & Carerj, S. (2015) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.2015.1024107 · Cited by 5
Relation of quality of anticoagulation control with different management systems among patients with atrial fibrillation: Data from FANTASIIA Registry
Rabadán, I. R., Esteve‐Pastor, M. A., Anguita-Sánchez, M. P., Muñiz, J., Siles, J. C., Simón, M. A. Q., Ortiz, M. R., Marín, F. R., Martínez‐Sellés, M., Bertoméu, V., et al. (2018) · European Journal of Clinical Investigation · doi:10.1111/eci.12910 · Cited by 5
Nine-Year Trends in Atrial Fibrillation Prevalence among Romanian Adult Hypertensives: A Post-Hoc Analysis of SEPHAR II-IV Surveys
Cojocaru, C., Vijiiac, A. E., Fronea, O. F. G., Mohaiu, A. T., Lucian Mihai, I. T. U., & Dorobanţu, M. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph19159250 · Cited by 5
Baseline demographics of a contemporary Belgian atrial fibrillation cohort included in a large randomised clinical trial on targeted education and integrated care (AF-EduCare/AF-EduApp study)
Delesie, M., Knaepen, L., Dendale, P., Vijgen, J. M., Ector, J., Desteghe, L., & Heidbüchel, H. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1186453 · Cited by 5
Patients with atrial fibrillation and CHA2DS2-VASc score 1: “To anticoagulate or not to anticoagulate? That is the question!”
Patti, G., & Cavallari, I. (2015) · Heart Rhythm · doi:10.1016/j.hrthm.2015.07.017 · Cited by 5
Risikoadaptierte Antikoagulation zur Schlaganfallprävention bei Vorhofflimmern in Deutschland, Österreich und der Schweiz
Steffel, J., Gwechenberger, M., Müller, M., Ammentorp, B., Darius, H., & Kirchhof, P. F. (2015) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/s-0041-108996 · Cited by 5
Antithrombotic treatment in anticoagulated atrial fibrillation patients undergoing percutaneous coronary intervention
Dézsi, C. A., Dézsi, B. B., & Dézsi, D. A. (2017) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2017.01.001 · Cited by 5
Recommended Methods for the Collection of Health State Utility Value Evidence in Clinical Studies
Ara, R., Brazier, J. E., & Young, T. A. (2017) · PharmacoEconomics · doi:10.1007/s40273-017-0549-6 · Cited by 5
A Narrative Review of Nonvitamin K Antagonist Oral Anticoagulant Use in Secondary Stroke Prevention
Caso, V., & Masuhr, F. (2019) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2019.05.017 · Cited by 5
Relative Impact of Bleedings Over Ischaemic Events in Patients with Heart Failure: Insights from the CARDIONOR Registry
Lemesle, G., Ninni, S., de Groote, P., Schurtz, G., Lamblin, N., & Bauters, C. (2020) · ESC Heart Failure · doi:10.1002/ehf2.12971 · Cited by 5
Use of NOACS in high-risk patients with atrial fibrillation in Saudi Arabia: Perspectives on improving patient care
Alshoaibi, N., Harbi, M. A., Modaimegh, H., AlQubbany, A., Saif, S. A., Connolly, D. L., Kharabsheh, S. M., Fathy, M., Hegazy, Y., Tarcha, N., et al. (2021) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2021.1878878 · Cited by 5
Value of cystatin C in predicting atrial fibrillation recurrence after radiofrequency catheter ablation.
Jin, L., You, L., & Xie, R.-Q. (2018) · Europe PMC (PubMed Central) · doi:10.11909/j.issn.1671-5411.2018.12.008 · Cited by 5
Non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation in secondary stroke and systemic embolism prevention
Gorczyca−Michta, I., Michalska, A., Chrapek, M., Jelonek, O. E., Wałek, P., & Wożakowska−Kapłon, B. (2019) · Cardiology Journal · doi:10.5603/cj.a2019.0069 · Cited by 5
Clinical benefits and risks of antithrombotic therapy in patients with atrial fibrillation with comorbidities – A report from the CHART-2 Study
Shiroto, T., Sakata, Y., Nochioka, K., Abe, R., Kasahara, S., Sato, M., Aoyanagi, H., Fujihashi, T., Yamanaka, S., Hayashi, H., et al. (2019) · International Journal of Cardiology · doi:10.1016/j.ijcard.2019.09.022 · Cited by 5
Anticoagulant Initiation During Hospital Admissions for Atrial Fibrillation in South-East Queensland, Australia
Rathinam, I., Anoopkumar‐Dukie, S., Badrick, T. C., Teasdale, T. L., & Bernaitis, N. (2020) · Heart Lung and Circulation · doi:10.1016/j.hlc.2020.03.009 · Cited by 5
Incidence and cost of bleeding events requiring hospitalization in patients with atrial fibrillation treated with acenocoumarol in Greece
Kourlaba, G., Stefanou, G., Tsalamandris, S., Oikonomou, E. K., Papageorgiou, G., Nikas, N., Tousoulis, D., & Maniadakis, N. (2020) · Hellenic Journal of Cardiology · doi:10.1016/j.hjc.2020.06.013 · Cited by 5
Atrial Fibrillation: The Year of 2021 in Review
Sardana, M., & Doshi, R. N. (2022) · Journal of Innovations in Cardiac Rhythm Management · doi:10.19102/icrm.2022.130108 · Cited by 5
Mechanisms of ST-segment elevation myocardial infarction in patients with atrial fibrillation, prior stenting and long-standing chronic coronary syndrome
Franchina, A. G., Calderone, D., D'Arrigo, P., Ingala, S., Milluzzo, R. P., Greco, A., Spagnolo, M., Tamburino, C., & Capodanno, D. (2020) · Cardiology Journal · doi:10.5603/cj.a2020.0002 · Cited by 5
Symptom management strategies: Rhythm vs rate control in patients with atrial fibrillation in the Balkan region: Data from the BALKAN‐AF survey
Kozieł, M., Mihajlovic, M., Nedeljkovic, M. A., Pavlović, N., Paparisto, V., Musić, L., Trendafilova, E., Dan, A. R., Kušljugić, Z., Dan, G., et al. (2021) · International Journal of Clinical Practice · doi:10.1111/ijcp.14080 · Cited by 4
Recognition and management of hemorrhaging in combination with emerging enterogenic sepsis during a hepatectomy: a case report
Chen, Y., Liao, Y., Chen, X., Fan, H., Lin, D., Zheng, T., Chen, X., Gong, C., Gao, F., Jiang, J., et al. (2023) · BMC Anesthesiology · doi:10.1186/s12871-023-02108-x · Cited by 4
Use of anticoagulants for atrial fibrillation in older subjects across different countries: Cyprus, France, Netherlands, Norway
Corvol, A., Gulsvik, A. K., Kuper, I. M. J. A., Phylaktou, P., Myrstad, M., Somme, D., & Cruz-Jentoft, A. J. (2013) · European Geriatric Medicine · doi:10.1016/j.eurger.2013.10.013 · Cited by 4
New oral anticoagulants for the prevention of thromboembolic complications in atrial fibrillation: a single centre experience
Gorczyca−Michta, I., & Wożakowska−Kapłon, B. (2015) · Kardiologia Polska · doi:10.5603/kp.a2014.0168 · Cited by 4
Treatment with oral anticoagulant drugs restrained from patients with atrial fibrillation: An assessment in a geographically well-defined catchment area
Andersson, P., & Löndahl, M. (2016) · European Journal of Preventive Cardiology · doi:10.1177/2047487316631395 · Cited by 4
Anticoagulation for the prevention of stroke in non-valvular AF in general practice: room for improvement
Ioannou, A., Metaxa, S., Kassianos, G. C., & Missouris, C. G. (2016) · Drugs in Context · doi:10.7573/di.212295 · Cited by 4
Management of patients with valvular and non-valvular atrial fibrillation in Poland: Results from Reference Cardiology University Center
Łopatowska, P., Tomaszuk−Kazberuk, A., Młodawska, E., Bachórzewska-Gajewska, H., Małyszko, J., Dobrzycki, S., & Musial, W. J. (2015) · Cardiology Journal · doi:10.5603/cj.a2014.0083 · Cited by 4
Risk Factors, Co-Morbidities and Treatment of In-Hospital Patients with Atrial Fibrillation in Bulgaria
Naydenov, S., Runev, N. M., Manov, Е., Vasileva, D., Rangelov, Y., & Naydenova, N. (2018) · Medicina · doi:10.3390/medicina54030034 · Cited by 4
Long-term health benefits of stroke prevention with apixaban versus vitamin K antagonist warfarin in patients with non-valvular atrial fibrillation in Germany: a population-based modelling study
Himmler, S., Müller, M., Ostwald, D. A., Seddik, A. H., Basic, E., & Hradetzky, E. (2018) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1080/14737167.2019.1522501 · Cited by 4
Risk of left atrial appendage thrombus in older patients with atrial fibrillation
Gawalko, M. M., Budnik, M., Uziębło‐Życzkowska, B., Gorczyca−Michta, I., Krzesiński, P., Ścisło, P., Kochanowski, J., Michalska, A., Jelonek, O. E., Starzyk, K., et al. (2021) · Archives of Medical Science · doi:10.5114/aoms/126028 · Cited by 4
Gastrointestinal bleeding during anticoagulation with direct oral anticoagulants compared to vitamin K antagonists
Dongre, K., Schmid, Y., Nussbaum, L., Winterhalder, C., Bassetti, S., Holbro, A., Degen, L. P., & Leuppi-Taegtmeyer, A. B. (2022) · Global Cardiology Science and Practice · doi:10.21542/gcsp.2022.21 · Cited by 4
Thromboembolism and bleeding risk scores and predictors of cardiac death in a population with atrial fibrillation
da Silva, R. M. F. L., Silva, P. A. E., Lima, M. C., Sant'Anna, L. T., Silva, T. C., Moreira, P. H. V., Gandra, R. M., Cavalcanti, T. R., & Mourão, P. H. V. (2017) · Arquivos Brasileiros de Cardiologia · doi:10.5935/abc.20170064 · Cited by 4
Exploring the Quality of Anticoagulant Prescribed for Patients With Atrial Fibrillation at the St John of God Hawkesbury District Health Centre, New South Wales, Australia
Wertheimer, G., & Bereznicki, L. (2018) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248418786264 · Cited by 4
Potential missed opportunities to prevent ischaemic stroke: prospective multicentre cohort study of atrial fibrillation-associated ischaemic stroke and TIA
Wilson, D., Ambler, G., Shakeshaft, C., Banerjee, G., Charidimou, A., Seiffge, D. J., White, M. J., Cohen, H., Yousry, T. A., Rustam, A.-S. S., et al. (2019) · BMJ Open · doi:10.1136/bmjopen-2018-028387 · Cited by 4
Influence of sex on long-term prognosis in patients with atrial fibrillation treated with oral anticoagulants. Results from the prospective, nationwide FANTASIIA study
Rabadán, I. R., Esteve‐Pastor, M. A., Sánchez, M. A., Muñiz, J., Ortiz, M. R., Marín, F. R., Roldán, V., Simón, M. A. Q., Siles, J. C., Cequier, A. R., et al. (2020) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2020.04.012 · Cited by 4
The affordability of adding a direct-acting oral anticoagulant to the national list of essential medicine for patients with non-valvular atrial fibrillation in Thailand: a budget impact analysis
Dilokthornsakul, P., & Permsuwan, U. (2021) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1080/14737167.2021.1883429 · Cited by 4
Implementation of oral anticoagulation treatment guidelines in patients with newly diagnosed atrial fibrillation
Arbel, A., Abu‐Ful, Z., Preis, M., Cohen, S., & Saliba, W. (2021) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14899 · Cited by 4
Assessment of Antithrombotic Therapy in Patients with Atrial Fibrillation for 2015-2017 According to the Registry of the Clinic of the Scientific Research Institute of Medical Problems of the North of Krasnoyarsk City
Tuchkov, A. A., Гоголашвили, Н. Г., & Yaskevich, R. A. (2019) · Rational Pharmacotherapy in Cardiology · doi:10.20996/1819-6446-2019-15-1-43-48 · Cited by 4
Clinical features of atrial fibrillation in obese hypertensives: results of a retrospective observational study
Petrischeva, E. Y., Ионин, В. А., Bliznuk, O. I., Pavlova, V. А., Skuridin, D. S., Ma, Y., Borisov, G. I., Zaslavskaya, E. L., & Баранова, Е. И. (2020) · Arterial’naya Gipertenziya (Arterial Hypertension) · doi:10.18705/1607-419x-2020-26-4-391-399 · Cited by 4
'Preferred' management of atrial fibrillation in Europe
Savelieva, I., & Camm, A. J. (2013) · EP Europace · doi:10.1093/europace/eut270 · Cited by 4
The Atrial Fibrillation Registry (The FLOW‐AF Registry): Insights From the United Arab Emirates—Patient Characteristics, Treatment, and One‐Year Outcomes
Kadri, M. E., Almuti, K., Agrawal, A., Bazargani, N., Gamaleldin, M. F. S., Ahmed, H. M., Hassanain, O., Khalife, N., Radaideh, G. A., Magdy, M., et al. (2025) · Journal of Cardiovascular Electrophysiology · doi:10.1111/jce.16598 · Cited by 3
Direct Oral Anticoagulants in Valvular Diseases and Prosthetic Valves: Why Not?
Lampropoulos, K. M., Penteris, M., & Gerotziafas, G. (2025) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-025-07736-8 · Cited by 3
Antithrombotic Strategies in Advanced Chronic Kidney Disease: Real-World Comparison of Oral Anticoagulation Alone vs Dual Antithrombotic Therapy
Kao, C. C. K. C.-C., Lin, H.-A., Hsu, C.-Y., & Lin, S. (2026) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2025.12.028 · Cited by 3
Novel oral anticoagulants and valvular atrial fibrillation: are they always contraindicated?
Pasquale, G. D., Zagnoni, S., & Riva, L. (2015) · Internal and Emergency Medicine · doi:10.1007/s11739-014-1181-5 · Cited by 3
Prescriptive behavior of non-vitamin K oral anticoagulants in patients affected by atrial fibrillation in general practice.
Rottura, M., Drago, S. F. A., Molonia, A., Irrera, N., Marino, S., Scoglio, R., Orlando, L., Fazio, M. G. D., Squadrito, F., Arcoraci, V., et al. (2023) · Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · doi:10.1016/j.biopha.2023.115020 · Cited by 3
Uso del tratamiento antitrombótico en pacientes con fibrilación auricular en atención primaria. Importancia del control del INR
Hernández, M. L., & Marín, F. R. (2014) · Revista Española de Cardiología · doi:10.1016/j.recesp.2014.02.004 · Cited by 3
Stroke prevention in atrial fibrillation: evidence from real-life studies: Table 1
Akao, M., Beyer‐Westendorf, J., Goto, S., & Peterson, E. D. (2015) · European Heart Journal Supplements · doi:10.1093/eurheartj/suv037 · Cited by 3
Risk of Coronary Events in Atrial Fibrillation
Kobalava, Z. D., & Lazarev, P. V. (2020) · Kardiologiia · doi:10.18087/cardio.2020.1.n828 · Cited by 3
Outcomes of Oral Anticoagulation in Atrial Fibrillation Patients With or Without Comorbid Vascular Disease: Insights From the GARFIELD-AF Registry
Verheugt, F. W. A., Fox, K. A. A., Virdone, S., Ambrosio, G., Gersh, B. J., Haas, S. K., Pieper, K. S., Kayani, G., Camm, A. J., Parkhomenko, A. N., et al. (2023) · The American Journal of Medicine · doi:10.1016/j.amjmed.2023.08.019 · Cited by 3
Clinical follow-up of atrial-fibrillation patients treated with novel oral anti-coagulants: A multi-disciplinary consensus from the Apulia section of the Italian Association of Hospital Cardiologists (ANMCO)
Gennaro, L. D., Modugno, G., Sportelli, G., Pellegrino, P. L., Iannone, A. M., Zamparella, M., Brunetti, N. D., & Caldarola, P. (2015) · International Journal of Cardiology · doi:10.1016/j.ijcard.2015.08.205 · Cited by 3
Electrocautery-induced ventricular fibrillation during routine implantable cardioverter-defibrillator generator replacement
Cassagneau, R., Hanninen, M., & Yee, R. (2013) · EP Europace · doi:10.1093/europace/eut267 · Cited by 3
Overcoming global challenges in stroke prophylaxis in atrial fibrillation: The role of non-vitamin K antagonist oral anticoagulants
Massaro, A. R., Giugliano, R. P., Norrving, B. G., Oto, A., & Veltkamp, R. C. (2016) · International Journal of Stroke · doi:10.1177/1747493016660106 · Cited by 3
Four-factor prothrombin complex concentrates: effectiveness in the reversal of anticoagulation
Gavva, C., Reddy, M. S., & Sarode, R. (2017) · International Journal of Clinical Transfusion Medicine · doi:10.2147/ijctm.s114736 · Cited by 3
Effect of Electrophysiology Assessment on Mortality and Hospitalizations in Patients With New-Onset Atrial Fibrillation
Singh, S. M., Webster, L. E., Qiu, F., Austin, P. C., Ko, D. T., Tu, J. V., & Wijeysundera, H. C. (2018) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2017.12.031 · Cited by 3
Anticoagulant and antiplatelet therapy choices for patients with atrial fibrillation one year after coronary stenting or acute coronary syndrome
Olivier, C. B., Turakhia, M. P., & Mahaffey, K. W. (2018) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2018.1424827 · Cited by 3
Cost and burden of poor anticoagulation control with vitamin K antagonists in patients with nonvalvular atrial fibrillation in Spain
Barrios, V., Cinza‐Sanjurjo, S., Gavín, O., Egocheaga, I., Burgos-Pol, R., Soto, J., Polanco, C., Suárez, J., & Casado, M. Á. (2020) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2020.06.033 · Cited by 3
Non-Clinical Factors Associated with International Normalized Ratio Control in Patients on Warfarin Therapy: A Review Paper
Ramasamy, T., Pillai, N. K., Yap, C. G., & Jahan, N. K. (2020) · OALib · doi:10.4236/oalib.1106947 · Cited by 3
Antithrombotic Treatment Patterns in Patients With Atrial Fibrillation in Italy pre- and post-DOACs: the Repair Study
Esposti, L. D., Brière, J., Bowrin, K., Sangiorgi, D., Perrone, V., & Pasquale, G. D. (2019) · Future Cardiology · doi:10.2217/fca-2018-0009 · Cited by 3
Stroke Prevention in Atrial Fibrillation in the Very Elderly: Anticoagulant Therapy Is No Longer a Sin
Ansell, J. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.117.006864 · Cited by 3
The RACE-3 is on: double-locking sinus rhythm by upstream and downstream therapy
Pavlović, D., Kirchhof, P. F., & Fabritz, L. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy018 · Cited by 3
The completeness of the left atrial appendage amputation during routine cardiac surgery
Radaković, D., Penov, K., Lazarus, M., Madrahimov, N., Hamouda, K., Schimmer, C., Leyh, R. G., & Bening, C. (2023) · BMC Cardiovascular Disorders · doi:10.1186/s12872-023-03330-8 · Cited by 2
Atrial Fibrillation Treatment Stratification Based on Artificial Intelligence‐Driven Analysis of the Electrophysiological Complexity
Nava, A., Ros, S., Carta‐Bergaz, A., González‐Torrecilla, E., Mansilla, A. G., Bermejo, J., Arenal, Á., Climent, A. M., Guillem, M. S., Atienza, F., et al. (2025) · Journal of Cardiovascular Electrophysiology · doi:10.1111/jce.16754 · Cited by 2
Long-term outcome and predictors for recurrence after medical and interventional treatment of arrhythmias at the UniverSity Heart CenTer Hamburg (TRUST): design and patient profile snapshot of a prospective clinical cohort study
Obergassel, J., Rieß, J. L., Jaeckle, S., van Elferen, S., Nies, M., Schenker, N., Lemoine, M. D., Welcker, A., Kany, S., Rottner, L., et al. (2026) · European Heart Journal Open · doi:10.1093/ehjopen/oeag002 · Cited by 2
2018 Korean Heart Rhythm Society Guidelines for The Rate Control of Atrial Fibrillation
Lim, W., Choi, E., Joung, B., & Choi, K. (2018) · Korean Journal of Medicine · doi:10.3904/kjm.2018.93.2.133 · Cited by 2
Clinical Characteristics And Health Care Resources In Patients Treated With Oral Anticoagulants: Evidences From Italian Administrative Databases
Esposti, L. D., Andretta, M., Pasquale, G. D., Gambera, M., Saragoni, S., Perrone, V., & Buda, S. (2019) · Vascular Health and Risk Management · doi:10.2147/vhrm.s216749 · Cited by 2

Authors: Kirchhof, P., Ammentorp, B., Darius, H., De Caterina, R., Le Heuzey, J.-Y., Schilling, R. J., Schmitt, J., & Zamorano, J. L.
Affiliations: University of Münster (DE)
Daiichi Sankyo (Germany) (DE)
Vivantes Klinikum (DE)
St Thomas' Hospital (GB)
Corresponding author: Kirchhof, Paulus
ORCID: Kirchhof, Paulus
Schilling, Richard John
Venue: EP Europace
Publisher: Oxford University Press (OUP)
Published: 2013-10-01
Volume: 16
Issue: 1
Pages: 6-14
ISSN: 1099-5129 (ISSN-L)
1532-2092
DOI: 10.1093/europace/eut263
PMC: PMC3864758
OpenAlex: W1973416160
Cited by: 404
References: 24
Citations by year: 2026: 3 · 2025: 8 · 2024: 16 · 2023: 15 · 2022: 20 · 2021: 31 · 2020: 46 · 2019: 27 · 2018: 36 · 2017: 59 · 2016: 44 · 2015: 56 · 2014: 36 · 2013: 6
FWCI: 32.15
Type: journal article
Language: en
Open access: hybrid
doi.org
Licence: cc-by-nc
Locations: EP Europace (publishedVersion, cc-by-nc)
Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
PubMed Central (publishedVersion, cc-by-nc)
PubMed (publishedVersion)
CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
Funders: Daiichi Sankyo Europe
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
Health Sciences › Medicine › Clinical Neurology › Acute Ischemic Stroke Management
Keywords: atrial fibrillation, clinical management, oral anticoagulation, vitamin K antagonists, direct oral anticoagulants, antiplatelet therapy, rate control, rhythm control, cardioversion, antiarrhythmic drugs, catheter ablation, guideline adherence, bleeding risk, CHA2DS2-VASc score
MeSH terms: Aged, Anticoagulants, Atrial Fibrillation, Cardiology, Europe, Female, Humans, Male, Practice Patterns, Physicians', Platelet Aggregation Inhibitors, Registries, Thromboembolism, Vitamin K, Comorbidity, Causality, Prevalence, Practice Guidelines as Topic, Guideline Adherence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Management of atrial fibrillation in seven European countries after the publication of the 2010 ESC Guidelines on atrial fibrillation: primary results of the PREvention oF thromboemolic events—European Registry in Atrial Fibrillation (PREFER in AF)

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks